A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events
The purpose of this trial is to compare the cardiovascular safety of insulin degludec to that of insulin glargine. Both are long acting insulin (basal insulin) products. Insulin degludec is produced by Novo Nordisk. Insulin degludec has not been approved by the U.S. Food and Drug Administration (FDA) and is considered experimental in this trial. For more information please contact Sarah Long at 352-273-8932 or at firstname.lastname@example.org. http://diabetes.ufl.edu/research/find-a-diabetes-research-study/
Keywordsinsulin, cardiovasucular, diabetes
Principal InvestigatorMargaret C Lo, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.